327 related articles for article (PubMed ID: 24374008)
1. Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
Seyler C; Li J; Schweizer PA; Katus HA; Thomas D
Eur J Pharmacol; 2014 Feb; 724():51-7. PubMed ID: 24374008
[TBL] [Abstract][Full Text] [Related]
2. Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.
Seyler C; Schweizer PA; Zitron E; Katus HA; Thomas D
Biochem Biophys Res Commun; 2014 Aug; 451(3):415-20. PubMed ID: 25108155
[TBL] [Abstract][Full Text] [Related]
3. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.
Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
Eur J Pharmacol; 2013 Dec; 721(1-3):237-48. PubMed ID: 24070813
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
[TBL] [Abstract][Full Text] [Related]
5. Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.
Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
Naunyn Schmiedebergs Arch Pharmacol; 2012 Oct; 385(10):1003-16. PubMed ID: 22790794
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels.
Staudacher K; Staudacher I; Ficker E; Seyler C; Gierten J; Kisselbach J; Rahm AK; Trappe K; Schweizer PA; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2011 Jul; 163(5):1099-110. PubMed ID: 21410455
[TBL] [Abstract][Full Text] [Related]
7. Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.
Schmidt C; Wiedmann F; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
Life Sci; 2014 Mar; 97(2):107-15. PubMed ID: 24345461
[TBL] [Abstract][Full Text] [Related]
8. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
[TBL] [Abstract][Full Text] [Related]
9. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K
Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D
J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues.
Lynch JJ; Regan CP; Beatch GN; Gleim GW; Morabito CJ
J Cardiovasc Pharmacol; 2013 Mar; 61(3):226-32. PubMed ID: 23188129
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.
Eldstrom J; Wang Z; Xu H; Pourrier M; Ezrin A; Gibson K; Fedida D
Mol Pharmacol; 2007 Dec; 72(6):1522-34. PubMed ID: 17872968
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular pharmacology of K
Staudacher I; Illg C; Chai S; Deschenes I; Seehausen S; Gramlich D; Müller ME; Wieder T; Rahm AK; Mayer C; Schweizer PA; Katus HA; Thomas D
Naunyn Schmiedebergs Arch Pharmacol; 2018 Oct; 391(10):1119-1131. PubMed ID: 30008082
[TBL] [Abstract][Full Text] [Related]
13. The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.
Gierten J; Ficker E; Bloehs R; Schweizer PA; Zitron E; Scholz E; Karle C; Katus HA; Thomas D
Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):261-70. PubMed ID: 19777211
[TBL] [Abstract][Full Text] [Related]
14. Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein.
Gierten J; Ficker E; Bloehs R; Schlömer K; Kathöfer S; Scholz E; Zitron E; Kiesecker C; Bauer A; Becker R; Katus HA; Karle CA; Thomas D
Br J Pharmacol; 2008 Aug; 154(8):1680-90. PubMed ID: 18516069
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of K2P2.1 (TREK1) background currents expressed in Xenopus oocytes by voltage-gated K+ channel β subunits.
Kisselbach J; Schweizer PA; Gerstberger R; Becker R; Katus HA; Thomas D
Life Sci; 2012 Oct; 91(11-12):377-383. PubMed ID: 22910181
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
[TBL] [Abstract][Full Text] [Related]
17. Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K
Wiedmann F; Schulte JS; Gomes B; Zafeiriou MP; Ratte A; Rathjens F; Fehrmann E; Scholz B; Voigt N; Müller FU; Thomas D; Katus HA; Schmidt C
Basic Res Cardiol; 2018 Jun; 113(4):27. PubMed ID: 29881975
[TBL] [Abstract][Full Text] [Related]
18. [Cardiac two-pore-domain potassium channels (K2P): Physiology, pharmacology, and therapeutic potential].
Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
Dtsch Med Wochenschr; 2012 Aug; 137(33):1654-8. PubMed ID: 22875694
[TBL] [Abstract][Full Text] [Related]
19. Vernakalant in the management of atrial fibrillation.
Cheng JW
Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the in vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model.
Allison B; Yang Y; Pourrier M; Gibson JK
J Cardiovasc Pharmacol; 2011 Apr; 57(4):463-8. PubMed ID: 21283020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
